AMYT:NSD-Amryt Pharma Holdings Ltd (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 7.00

Change

+0.20 (+2.94)%

Market Cap

USD 0.44B

Volume

9.19K

Avg Analyst Target

USD 19.00 (+171.43%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AMYT Stock Forecast & Price:
Based on the Amryt Pharma Holdings Ltd stock forecasts from 1 analysts, the average analyst target price for Amryt Pharma Holdings Ltd is USD 19.00 over the next 12 months. Amryt Pharma Holdings Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Amryt Pharma Holdings Ltd is Neutral, which is based on 5 positive signals and 6 negative signals. At the last closing, Amryt Pharma Holdings Ltd’s stock price was USD 7.00. Amryt Pharma Holdings Ltd’s stock price has changed by -6.67% over the past week, -8.02% over the past month and -42.67% over the last year.

About Amryt Pharma Holdings Ltd (AMYT:NSD)

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therap ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-27 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
PPD PPD Inc

N/A

USD16.61B 47.04 21.58
VTRS Viatris Inc

-0.05 (-0.59%)

USD10.54B 13.79 6.52
NBIX Neurocrine Biosciences Inc

+0.79 (+0.79%)

USD9.62B 773.62 207.84
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
LNTH Lantheus Holdings Inc

+0.79 (+1.19%)

USD4.62B 172.41 41.49
ITCI Intracellular Th

+1.88 (+4.40%)

USD4.11B N/A -10.69
ALKS Alkermes Plc

+0.02 (+0.09%)

USD3.67B N/A -220.20
EVO Evotec SE ADR

+0.03 (+0.36%)

USD3.08B 429.00 64.49

ETFs Containing AMYT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -35.19% 65% D 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.19% 64% D 43% F
Trailing 12 Months  
Capital Gain -39.86% 68% D+ 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.86% 68% D+ 43% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -13.78% 44% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.78% 43% F 20% F
Risk Return Profile  
Volatility (Standard Deviation) 16.62% 97% A+ 76% C
Risk Adjusted Return -82.93% 22% F 6% F
Market Capitalization 0.44B 71% C- 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 23.71 35% F 38% F
Price/Book Ratio 1.28 54% F 61% D-
Price / Cash Flow Ratio 28.41 9% F 8% F
EV/EBITDA 8.05 18% F 27% F
Management Effectiveness  
Return on Equity 1.43% 81% B- 58% F
Return on Invested Capital -15.06% 61% D- 38% F
Return on Assets -3.55% 67% D+ 43% F
Debt to Equity Ratio 59.03% 42% F 34% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.08 55% F 56% F
Short Percent 1.54% 70% C- 59% F
Beta 0.41 84% B 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.